Morningstar Investment Management LLC Has $4.16 Million Position in IQVIA Holdings Inc. $IQV

Morningstar Investment Management LLC reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,444 shares of the medical research company’s stock after selling 4,339 shares during the quarter. Morningstar Investment Management LLC’s holdings in IQVIA were worth $4,158,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Claret Asset Management Corp raised its position in IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after purchasing an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. raised its position in IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares during the last quarter. Brookstone Capital Management raised its position in IQVIA by 2.2% in the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock valued at $661,000 after purchasing an additional 63 shares during the last quarter. Private Advisor Group LLC raised its position in IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after purchasing an additional 63 shares during the last quarter. Finally, Keybank National Association OH raised its position in IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after purchasing an additional 67 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Up 0.2%

NYSE IQV opened at $168.28 on Monday. The stock has a fifty day moving average of $169.72 and a 200-day moving average of $197.45. The stock has a market capitalization of $28.09 billion, a P/E ratio of 20.85, a price-to-earnings-growth ratio of 1.61 and a beta of 1.18. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period last year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current year.

IQVIA announced that its Board of Directors has approved a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Stifel Nicolaus cut their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Citigroup cut their price objective on IQVIA from $230.00 to $200.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. Morgan Stanley set a $225.00 price objective on IQVIA in a research report on Thursday, May 7th. Royal Bank Of Canada assumed coverage on IQVIA in a research report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Finally, Jefferies Financial Group cut their price objective on IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.